4-(四氢-2H-吡喃-4-基氧基)苯甲腈 | 884507-34-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(四氢-2H-吡喃-4-基氧基)苯甲腈
• 英文名称: 4-((tetrahydro-2H-pyran-4-yl)oxy)benzonitrile
• 英文别名: 4-(Tetrahydropyran-4-yloxy)benzonitrile；4-(oxan-4-yloxy)benzonitrile
• CAS: 884507-34-0
• 化学式: C₁₂H₁₃NO₂
• mdl: MFCD09025875
• 分子量: 203.241
• InChiKey: ITXQSYHCKPGZLV-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C
• 沸点：
  364.8±32.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为产物：
  描述：

  [4-(四氢吡喃-4-氧基)苯基]甲醇 在 ammonium hydroxide 作用下， 以 叔丁醇 为溶剂， 120.0 ℃ 、1.0 MPa 条件下， 反应 24.0h， 以84%的产率得到4-(四氢-2H-吡喃-4-基氧基)苯甲腈
  参考文献：
  名称：

  用于有氧氧化合成（杂）芳香醛、酮、酯、酸、腈和酰胺的“通用”催化剂

  摘要：

  功能化（杂）芳族化合物是基础和应用科学中广泛使用的不可或缺的化学品。其中，尤其是芳香醛、酮、羧酸、酯、腈和酰胺是有价值的精细和大宗化学品，可用于化学、制药、农业化学和材料工业。对于它们的合成，醇的催化有氧氧化构成了一种绿色、可持续且具有成本效益的工艺，理想情况下应该利用活性和选择性的 3D 金属。在这里，我们报告了通过在碳上热解钴-哌嗪-酒石酸络合物作为最通用的氧化催化剂，制备包裹在 Co-纳米颗粒中的石墨层。这种独特的材料可以合成简单、功能化和结构多样的（杂）芳香醛、酮、

  DOI：

  10.1016/j.chempr.2021.12.001

文献信息

• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：Almstead Neil

  公开号：US20120202763A1

  公开（公告）日：2012-08-09

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文介绍了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物以及包含这些化合物的组合物。本文还介绍了抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的化合物以及包含这些化合物的组合物。同时，本文还介绍了使用这些化合物减少VEGF的方法以及使用这些化合物治疗癌症和非肿瘤性疾病的方法。本文还介绍了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的方法以及使用这些化合物治疗病毒感染的方法。这些化合物可以作为单一治疗剂或与一个或多个其他治疗剂联合使用，用于治疗需要这些治疗的人类。
• Methods for treating cancer and non-neoplastic conditions
  申请人：Almstead Neil

  公开号：US09351964B2

  公开（公告）日：2016-05-31

  Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文描述了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物，如式（I）的化合物，以及包含这些化合物的组合物。本文还描述了抑制病毒复制或病毒RNA或DNA或病毒蛋白质的产生的化合物，以及包含这些化合物的组合物。同时还描述了使用这些化合物减少VEGF的方法以及通过给予这些化合物治疗癌症和非肿瘤性疾病的方法。此外，还描述了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质的产生的方法以及通过给予这些化合物治疗病毒感染的方法。这些化合物可以作为单一药物治疗或与一个或多个其他治疗方法组合给予需要这些治疗的人类。
• METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION
  申请人：PTC Therapeutics, Inc.

  公开号：US20200317668A1

  公开（公告）日：2020-10-08

  Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein using such Compounds, and methods for treating viral infections, such as an RNA virus belonging to the family Coronaviridae, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
• US9351964B2
  申请人：——

  公开号：US9351964B2

  公开（公告）日：2016-05-31
• [EN] METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UN CANCER ET D'ÉTATS NON NÉOPLASIQUES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138758A1

  公开（公告）日：2010-12-02

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.